Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChemoID vs Standard Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT03949283Phase 3Active, not recruiting
- Sponsor
- Cordgenics LLC
- Start
- Jul 2019
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Cordgenics LLC. Primary endpoint: Objective Response Rate at 24 months. Started Jul 2019; status: active, not recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03949283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949283.